Trump’s two-term pharmaceutical plan to secure America’s medicines
We won't let overseas chokepoints cause U.S. drug shortages again
COMMENTARY
By Peter Navarro - Thursday, August 21, 2025
OPINION:
America cannot be secure, prosperous or sovereign if our medicine cabinet depends on foreign adversaries.
The pandemic emergency revealed the dangers of import dependence up and down the global drug chain. Hospitals rationed generics. Pharmacies couldn’t fill pediatric antibiotics. When Shanghai’s lockdown idled a single plant that makes the contrast dye used in computed tomography scans — the rapid X-ray images doctors use to spot strokes, clots and internal bleeding — U.S. hospitals spent weeks rationing scans. One overseas choke point rippled through American emergency rooms.
A lot of America’s generic medicines depend on active pharmaceutical ingredients sourced from China and India, and India relies heavily on Chinese inputs. That is a textbook strategic vulnerability.
President Trump’s strategy to address this vulnerability is three-pronged. First, his recent executive order readies and fills the Strategic Active Pharmaceutical Ingredients Reserve to stockpile the active pharmaceutical ingredients we need in a crisis. Second, the administration will harness federal purchasing to create durable demand for U.S.-made medicines. Third, we will harden supply by accelerating advanced manufacturing and building an early warning system for shortages.
On execution, the Administration for Strategic Preparedness and Response, overseen by the Health and Human Services Department, will identify roughly 26 especially critical drugs, update its 2022 list of 86 essential medicines and medical countermeasures, ready the Strategic Active Pharmaceutical Ingredients Reserve repository and, subject to available funds, acquire and maintain a six-month supply of active pharmaceutical ingredients. The Administration for Strategic Preparedness and Response will propose and cost out a second repository to eliminate single points of failure.
The reserve’s mission is simple: Maintain a reliable six-month buffer of active pharmaceutical ingredients so we can surge finished doses when a plant goes down, a port closes or an adversary tries to twist a supply chain screw.
To create durable demand, the administration will align the Department of Health and Human Services, the Veterans Affairs Department and the Defense Department, together the nation’s largest public purchasers of medicines, around multiyear procurements that prioritize U.S.-made active pharmaceutical ingredients and finished doses for a defined set of mission-critical generics. Predictable federal purchasing is the bridge that makes new domestic capacity financeable.
To harden supply, we will deploy Defense Production Act Title III tools to co-fund advanced and continuous manufacturing capacity, press for expedited Food and Drug Administration pathways for those technologies and stand up a national early warning system that detects and prevents shortages before they hit the bedside. The Treasury and Commerce departments will align tax and financing tools to reward onshoring and modernization, and the Department of Homeland Security and the Department of Energy will treat these plants as critical infrastructure, with the cyber and physical security standards they deserve.
...
READ MORE: https://www.washingtontimes.com/news/2025/aug/21/trumps-two-term-pharmaceutical-plan-secure-americas-medicines/
***
Chân thành cám ơn Quý Anh Chị ghé thăm "conbenho Nguyễn Hoài Trang Blog"
Xin được lắng nghe ý kiến chia sẻ của Quý Anh Chị trực tiếp tại Diễn Đàn Paltalk: 1Latdo Tapdoan Vietgian CSVN Phanquoc Bannuoc.
Kính Chúc Sức Khỏe Quý Anh Chị.
conbenho
Tiểu Muội quantu
Nguyễn Hoài Trang
23082025
__________________________
Cộng sản Việt Nam là TỘI ÁC
Bao che, dung dưỡng TỘI ÁC là ĐỒNG LÕA với TỘI ÁC
No comments:
Post a Comment